
[ad_1]
MONDAY, April 8, 2024 (HealthDay News) — For patients with acute myocardial infarction who are at risk for heart failure, empagliflozin reduces the risk of hospitalization for heart failure, according to study results published online April 6. . Circulation The event will be held in conjunction with the American College of Cardiology’s annual meeting in Atlanta, April 6-8.
Adrian Hernandez, M.D., of Duke University in Durham, North Carolina, and colleagues investigated the effects of empagliflozin on first and recurrent heart failure events in patients after myocardial infarction in a double-blind, randomized trial. The study included 6,522 patients admitted with acute myocardial infarction who were at risk for heart failure based on new-onset left ventricular ejection fraction of less than 45 percent and/or signs and symptoms of congestion.
The researchers found that during a median follow-up of 17.9 months, the risk of first heart failure hospitalization and total heart failure hospitalization was significantly lower in the empagliflozin group versus the placebo group (hazard ratio for first heart failure hospitalization, 0.77; rate ratio and 0.67 for total heart failure hospitalizations). For first-time and complete heart failure hospitalizations, the benefits of empagliflozin were consistent across clinically relevant patient subgroups. Patients randomly assigned to empagliflozin were less likely to require new use of diuretics, renin-angiotensin modulators, or mineralocorticoid receptor antagonists after discharge.
“These data suggest that empagliflozin may have a potential role in preventing heart failure hospitalization in high-risk post-myocardial infarction patients,” the authors wrote.
Several authors disclosed relationships with biopharmaceutical companies, such as Boehringer Ingelheim and Eli Lilly, that manufacture empagliflozin and fund research.
Summary/Full text
For more information
Copyright © 2024 HealthDay. All rights reserved.
[ad_2]
Source link